Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant, non-nursing female patients at least 18 years of age~* Diagnosis of axial spondyloarthritis according to Ankylosing SpondyloArthritis International Society (ASAS) axial spondyloarthritis criteria~* objective signs of inflammation (magnetic resonance imaging (MRI) or abnormal C-reactive protein)~* active axial spondyloarthritis as assessed by total Bath Ankylosing Spondylitis Disease Activity Index \>=4 cm~* Spinal pain as measured by Bath Ankylosing Spondylitis Disease Activity Index question #2 ≥ 4 cm (0-10 cm) at baseline~* Total back pain as measured by Visual Analogue scale ≥ 40 mm (0-100 mm) at baseline~* Patients should have been on at least 2 different non-steroidal anti-inflammatory drugs with an inadequate response~* Patients who have been on a Tumor Necrosis Factor (TNF) α inhibitor (not more than one) must have experienced an inadequate response~Exclusion Criteria:~* Patients with radiographic evidence for sacroiliitis, grade ≥ 2 bilaterally or grade ≥ 3 unilaterally~* Inability or unwillingness to undergo MRI~* Chest X-ray or MRI with evidence of ongoing infectious or malignant process~* Patients taking high potency opioid analgesics~* Previous exposure to secukinumab or any other biologic drug directly targeting interleukin-17 (IL-17) or IL-17 receptor~* Pregnant or nursing (lactating) women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab, 150 mg Load (Core phase) (Type: EXPERIMENTAL): Secukinumab 150 mg s.c., pre-filled syringe (PFS) at baseline, Weeks 1, 2, and 3, followed by administration every four weeks starting at Week 4, Load, Core phase
- Secukinumab, 150 mg No Load (Core phase) (Type: EXPERIMENTAL): Secukinumab 150 mg s.c. PFS at baseline, placebo at Weeks 1, 2, and 3, followed by secukinumab 150 mg PFS administration every four weeks starting at Week 4, No Load, Core phase
- Placebo (Core phase) (Type: PLACEBO_COMPARATOR): Placebo s.c., PFS at baseline, Weeks 1, 2, 3, followed by administration every four weeks starting at Week 4, Core phase
- Core Phase Responder 150 mg (Extension phase) (Type: EXPERIMENTAL): Core Phase Responder 150 mg blinded: secukinumab 150 mg s.c. PFS and placebo (1 mL) s.c. PFS every four weeks, in the Extension phase
- Core Phase Responder 300 mg (Extension phase) (Type: EXPERIMENTAL): Core Phase Responder 300 mg blinded: 2 injections with secukinumab 150 mg s.c. PFS every four weeks, in the Extension phase
- Core Phase Non-Responder 300 mg (Extension phase) (Type: EXPERIMENTAL): Core Phase Non-Responder 300 mg: 2 injections with secukinumab 150 mg s.c. PFS every four weeks open-label, in the Extension phase

Based on this trial design, predict the completion outcome and termination type (if applicable).